Particulate Matter Contamination Leads to Argatroban Recall

Four lots of the blood thinner Argatroban have been recalled due to particulate matter contamination. 

The Argatroban recall was announced by the FDA on March 23, after visible particles were spotted in some vials during inspections that occurred after the distributor received a complaint. The recall was issued by Eagle Pharmaceuticals, Inc., supplier to The Medicines Company.

Argatroban is an anticoagulant used to prevent or treat thrombosis caused by the drug heparin. It was first approved by the FDA in 2000.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

The FDA warns that the risk of using an injectable drug that has been contaminated with particulate matter could include embolization and infarction to organs, which could cause severe injury. There have been no reports of injuries related to the recalled Argatroban.

Four lots of Argatroban Injection, 50 mg per 50 mL, are affected by the recall, including lot numbers V10189, V10191 and V10194 with expiration dates of Jan 2013, and lot number V10223 with an expiration date of Feb 2013.

Eagle Pharmaceuticals Inc. has asked The Medicines Company to arrange for the affected vials to be returned from services and facilities that received them. The recall is being conducted at the wholesaler, pharmacy and distributor levels.

Customers with questions can contact The Medicines Company at (888) 977-6326 or via e-mail at argatrobanrecall@themedco.com. Adverse events related to the use of this product should be reported to the FDA’s adverse event reporting program, MedWatch.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal
BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal (Posted 2 days ago)

A BioZorb lawsuit has been filed by several breast cancer survivors after the BioZorb implants moved out of place and failed to dissolve int he body, requiring surgical removal.

Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October
Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October (Posted 2 days ago)

A U.S. District Court judge has scheduled a fairness hearing for October in order to determine whether final approval should be granted to a $25 million Philips CPAP recall settlement agreement, which would pay former users $25 million to pay for future medical monitoring needs.